NEW YORK, March 13 (GenomeWeb News) - FoxHollow Technologies has licensed the Rosetta Resolver system for research on cardiovascular disease, Rosetta Biosoftware said today.
FoxHollow will use the application to correlate genetic profiles of human atherosclerotic plaque samples to develop therapies, according to a statement. The data for analysis comes from a September 2005 pharmacogenomic collaboration between FoxHollow and Merck.
Financial details were not released.
Rosetta Biosoftware is a business unit of Rosetta Inpharmatics, which is a wholly owned subsidiary of Merck.